138 related articles for article (PubMed ID: 18563330)
1. Effect of survivin regulation of transcription level by p21waf1 overexpression in HepG2 hepatocellular carcinoma cells.
Xiong J; Hu L; Li Y; Dou L; Cai P; Tang Z; Wang L
J Huazhong Univ Sci Technolog Med Sci; 2008 Jun; 28(3):308-13. PubMed ID: 18563330
[TBL] [Abstract][Full Text] [Related]
2. [The effect of p21 on transcription of survivin in hepatocellular carcinoma HepG2 cells and its regulation mechanism].
Xiong J; Li YR; Tang ZM; Dou LF; Wang L; Hu LH
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):583-7. PubMed ID: 19102934
[TBL] [Abstract][Full Text] [Related]
3. [Effect of inhibiting survivin expression with antisense oligodeoxynucleotides on sensitivity of hepatocellular carcinoma cell lines HepG2 and HepG2/ADM to adriamycin].
Dai DJ; Lu CD; Guo JM; Zhang J
Ai Zheng; 2005 Aug; 24(8):951-7. PubMed ID: 16086872
[TBL] [Abstract][Full Text] [Related]
4. [Synergistic inhibitory effect of all-trans retinoic acid and 1,25-dihydroxy vitamin D3 on growth of human hepatoma cell line HepG2].
Lu HQ; Zheng J
Ai Zheng; 2006 Dec; 25(12):1470-6. PubMed ID: 17166369
[TBL] [Abstract][Full Text] [Related]
5. A novel all-trans retinoic acid derivative 4-amino‑2‑trifluoromethyl-phenyl retinate inhibits the proliferation of human hepatocellular carcinoma HepG2 cells by inducing G0/G1 cell cycle arrest and apoptosis via upregulation of p53 and ASPP1 and downregulation of iASPP.
Liu H; Chen F; Zhang L; Zhou Q; Gui S; Wang Y
Oncol Rep; 2016 Jul; 36(1):333-41. PubMed ID: 27177208
[TBL] [Abstract][Full Text] [Related]
6. Survivin promotes cell proliferation in human hepatocellular carcinoma.
Ito T; Shiraki K; Sugimoto K; Yamanaka T; Fujikawa K; Ito M; Takase K; Moriyama M; Kawano H; Hayashida M; Nakano T; Suzuki A
Hepatology; 2000 May; 31(5):1080-5. PubMed ID: 10796883
[TBL] [Abstract][Full Text] [Related]
7. [Inhibitory effect of adriamycin combined P21CIP1 gene transfection on proliferation of human hepatoblastoma cell line HepG2].
; ; . PubMed ID: 18479596
[TBL] [Abstract][Full Text] [Related]
8.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
9.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
10.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
